Who can use pemazyre(pemigatinib)?

Cholangiocarcinoma

Pemigatinib is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma that is unresectable, has received prior treatment, and harbors fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements detected by an FDA-approved test.

Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Pemigatinib is indicated for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLN) harboring fibroblast growth factor receptor 1 (FGFR1) rearrangements.